Avocado-Soybean Unsaponifiables

PIASCLEDINE-ExpASU®, a type of avocado/soybean unsaponifiable product, displays superior pharmacological activity due to its unique composition, including a high inhibitory effect on pro-inflammatory factors.

2022 Frontiers in Pharmacology Composition Analysis and Pharmacological Activity of Avocado/Soybean Unsaponifiable Products Used in the Treatment of Osteoarthritis Lambert C, Bellemère G, Boyer G, Ponelle F, Bauer T, Legeny MC, et al.

Experimental Study Osteoarthritis

The study began with the characterisation of the lipid content of seven different avocado/soybean unsaponifiable (ASU) products through gas chromatography analysis performed on a VARIAN 3400 chromatograph. In parallel, the effects of these products were tested on human osteoarthritis chondrocytes (cartilage cells) cultured in alginate beads. The researchers focused on the effects of these ASU products on aggrecan, key interleukins, and matrix metalloproteases.

In terms of results, PIASCLEDINE-ExpASU® stood out due to a specific profile involving unique chromatographic peaks and the presence of specific compounds like alkyl furan fraction, alkyl triols, and squalene. Remarkably, this product showed heightened efficacy in inhibiting production of nitric oxide, interleukins, and catabolic factors. Meanwhile, excepting two products, the remaining ASUs showed varied capacity in increasing aggrecan production, a positive factor in the context of osteoarthritis treatment.

View Article

Avocado and soybean unsaponifiables may effectively reduce inflammation and symptoms related to osteoarthritis, autoimmune diseases, and menopause.

2020 Biomolecules Avocado–Soybean Unsaponifiables: A Panoply of Potentialities to Be Exploited Salehi B, Rescigno A, Dettori T, Calina D, Docea AO, Singh L, et al.

Review Article Autoimmune Disease Menopause Osteoarthritis

The research involves summarizing various studies on the biological effects of the avocado-soybean unsaponifiables (ASU), highlighting its potent anti-inflammatory properties. The extracted ASU are a combination of elements derived from the fruits and seeds of avocados and soybeans. To understand its impact, the researchers categorized the applications of ASU in treating different conditions such as osteoarthritic pain, hip and knee osteoarthritis, autoimmune diseases, and menopause-related symptoms amongst postmenopausal women.

The discussion revealed significant links between avocado and soybean unsaponifiables and symptom improvement in areas of osteoarthritic pain, autoimmune conditions, and postmenopause. Particularly notable is the ASU mixture's potential role as an adjunct treatment, meaning it’s meant to supplement primary treatments for such conditions. Its benefits were not only limited to physical reduction of inflammation and associated pain, but also improved mood and quality of life for postmenopausal women by significantly reducing menopause-related symptoms. The study also delves into the safety, toxicological considerations, and regulatory practices related to the use of ASU.

View Article

Avocado-soybean unsaponifiables treatment is effective in reducing knee osteoarthritis symptoms without increasing adverse events, contrary to those with hip osteoarthritis.

2019 International Journal of Rheumatic Diseases Efficacy and safety of avocado‐soybean unsaponifiables for the treatment of hip and knee osteoarthritis: A systematic review and meta‐analysis of randomized placebo‐controlled trials Simental‐Mendía M, Sánchez‐García A, Acosta‐Olivo CA, Vilchez‐Cavazos F, Osuna‐Garate J, Peña‐Martínez VM, et al.

Systematic Review Avocado Knee Osteoarthritis Osteoarthritis

To assess avocado-soybean unsaponifiables (ASU) effectiveness and safety, a systematic review and meta-analysis of randomized controlled trials involving patients with hip or knee osteoarthritis was conducted. Various scientific databases, including Medline, SCOPUS, Web of Science, and Google Scholar, were thoroughly searched for suitable trials. Selection criteria consisted of randomized placebo-controlled trials wherein the effect of orally administered ASU on knee or hip osteoarthritis symptoms were evaluated, primarily using the Lequesne index, visual analog scale, and joint space width.

The meta-analysis revealed a significant reduction in pain as assessed by the visual analog scale for those under Avocado-soybean unsaponifiables therapy, particularly for patients with knee osteoarthritis, indicated by a decrease in both the visual analogue scale and Lequesne index. However, no such significant effect was found for patients with hip osteoarthritis. In terms of safety, there were no significant differences in adverse events between patients receiving ASU and those given a placebo, confirming ASU's relative safety as a treatment option.

View Article

A dietary supplement Avocado/Soybean Unsaponifiables aids in treating Osteoarthritis by preventing cartilage degradation and promoting cartilage repair, thereby reducing pain and enhancing joint functionality.

2014 CARTILAGE Management of Osteoarthritis with Avocado/Soybean Unsaponifiables Christiansen BA, Bhatti S, Goudarzi R, Emami S

Review Article Articular Cartilage Avocado

Avocado/Soybean Unsaponifiables was studied for its effects on Osteoarthritis. The methodology highlighted its functions, which include inhibiting the release and activity of molecules and pathways that are implicated in OA, as well as those that prevent cartilage degradation. These functions are principally through the prohibition of matrix metalloproteinases and the increase of tissue inhibitors of the catabolic enzymes in question. Additionally, ASU was found to inhibit fibrinolysis by stimulating the expression of plasminogen activator inhibitor. Moreover, its anabolic properties were credited with promoting cartilage repair by stimulating collagen and aggrecan synthesis while inhibiting inflammatory cytokines.

ASU's chondroprotective effects were noted as well; these effects are brought about by correcting growth factor abnormalities, and by simultaneously increasing Transforming Growth Factor-Beta in synovial fluid while decreasing vascular endothelial growth factor. Additionally, it was observed to inhibit cholesterol absorption and biosynthesis, which further contribute to its beneficial role by moderating reactive oxygen species pathology in chondrocytes.

Results indicated that the dietary supplement has significant therapeutic value for those suffering from Osteoarthritis. It reduces pain and stiffness while improving joint function, resulting in less dependency on painkillers. It was found that ASU's preventative measures towards cartilage degradation and its promotion of cartilage repair play essential roles in its efficiency as a treatment for OA.

View Article

The daily use of avocado-soybean unsaponifiable-expanscience (ASU-E) reduces the progression of joint space narrowing in patients with hip osteoarthritis.

2013 Annals of the Rheumatic Diseases Randomised, controlled trial of avocado–soybean unsaponifiable (Piascledine) effect on structure modification in hip osteoarthritis: the ERADIAS study Maheu E, Cadet C, Marty M, Moyse D, Kerloch I, Coste P, et al.

Randomised Controlled Trial Hip Osteoarthritis Osteoarthritis

The conducted trial was a prospective, randomised, double-blind study with parallel groups under placebo control over three years. The participants included symptomatic hip osteoarthritis patients having experienced pain for a minimum of one year and featuring a joint space width (JSW) between 1 and 4 mm in the affected hip. Participants were assigned randomly to a daily intake of 300 mg ASU-E or a placebo. Annual pelvic radiographs in standing position were performed, with the primary focus on the change in JSW at the end of year three.

Despite no significant difference in mean JSW loss between the ASU-E group and placebo, fewer progressors (patients with JSW loss of 0.5mm or more) were recorded in the ASU-E group, marking a 20% decrease compared to the placebo group. This indicates a potential therapeutic effect of ASU-E on the structural integrity of hip joints in osteoarthritis patients. However, clinical outcome comparisons did not yield any significant differences between the groups. The safety profile of ASU-E was determined to be excellent.

View Article